Clinical trials are key to translating scientific advances into progress in cancer research and care. Confronted by developments in basic science, the landscape of clinical cancer research is rapidly evolving. Here, we review recent changes in clinical trials' design and conduct, and we forecast future directions toward personalized and global impact.
Introduction
Many of the discoveries in cancer science are touted as potential avenues toward improved clinical therapies. Indeed, revolutionary advancements in technologies for the characterization of cancer genomes (e.g., next-generation sequencing), increasing application of more robust models of clinical disease (e.g., patient-derived xenografts and organoids), and the development of powerful tools for the functional evaluation of cancer targets (e.g., CRISPR/Cas9) have had a major impact on the direction and process of nonclinical anticancer drug development. Simultaneously, the dawn of the cancer immunotherapy era has seized the attention of the research community and is now a major focus for target validation and drug discovery. Despite these changing landscapes, clinical evaluation of new agents remains the cornerstone of drug development, and thus well-designed clinical trials are essential to deliver new medicines to patients in need.
The scope of clinical investigation in oncology is enormous, with approximately 830 anticancer agents in clinical trials or under review by the US Food and Drug Administration in 2015 (www.phrma. org/report/medicines-in-developmentfor-cancer-2015-report). While historically the paradigm of anticancer drug development has taken 10 years or longer from first-in-human Phase I studies to regulatory approval, this pace is no longer acceptable to stakeholders, including industry, investigators, patients, and advocates. In this Commentary, we will review some of the important trends in the design and conduct of clinical trials over the last decade and anticipate areas for continued innovation in the coming years. In doing so, we hope to identify opportunities to address the urgent need to translate emerging science into therapeutic improvements.
Changes in the Design and Conduct of Clinical Trials in the Last Decade
The traditional, sequential three-phase drug development paradigm has reigned in oncology for more than five decades, since the development of the Phase II concept proposed by Gehan at the National Cancer Institute in 1961 (Gehan, 1961) . Therein, the tolerability, pharmacokinetics, and safely administered doses of new drugs are determined through dose escalation in Phase I studies, typically in unselected patients with treatment refractory disease. Agents graduating based on the above properties move to Phase II studies in order to estimate antitumor efficacy in a more homogeneous, usually histologically defined population. Finally, the effectiveness of a treatment compared to existing standard of care is assessed in Phase III, typically randomized trials. However, driven by an urgency to bring effective therapies to patients, an increasing number of agents with potential breakthrough anticancer activity have challenged the sequential three-phase paradigm. The two major ways that this has occurred are exemplified by the development of recently approved immune checkpoint inhibitors (e.g., pembrolizumab) and agents targeting rare and specific molecular alterations (e.g., crizotinib). Both of these agents took only 3-4 years from first-in-human testing to regulatory approval, a timeline that was unprecedented for solid tumors (Kazandjian et al., 2014; Poole, 2014) .
Seamless Development in Phase I First-in-Human Trials
In contrast to a typical Phase I trial, which might enroll a few dozen patients, the first-in-human study of pembrolizumab, KEYNOTE-001, evolved into a massive, multi-armed expansion study enrolling more than 1,200 patients. A clinical protocol need not be static and unchanging and can be adapted to incorporate emerging science and clinical data, especially for agents demonstrating early signs of promising antitumor activity and acceptable toxicity. The flexibility to amend in-progress studies with regulatory approval must be accompanied by a clear and strong rationale to alter existent design and justify the expansion. KEYNOTE-001 is an example of a welltolerated agent with substantial clinical activity, where serial protocol amendments were deemed to be more expeditious than re-launching later-stage trials. What began as a standard 3+3 dose escalation study with three dose levels and a planned seven-patient expansion in each of two disease-specific cohorts (melanoma and renal cell carcinoma) ultimately enrolled 40 times as many patients, including 655 with advanced melanoma and 550 with non-small lung cancer (NSCLC), and supported the accelerated approval of pembrolizumab for these two indications (Garon et al., 2015; Hamid et al., 2013) . In addition, numerous Phase II and III trials were launched while KEYNOTE-001 was ongoing. Accelerated Approval from SingleArm Studies While immune checkpoint inhibitors such as anti-programmed death-1 (PD1) and anti-programmed death ligand-1 (PD-L1) antibodies appear to have broad activity across several cancer types, agents targeting very specific molecular alterations represent the other end of the drug development spectrum. Imatinib, the standardbearer of personalized cancer therapy, initially received accelerated approval for chronic myelogenous leukemia (CML) driven by the BCR-ABL translocation on the basis of open-label, single-arm Phase II studies (Johnson et al., 2003) . The discovery of EML4-ALK fusions in a small proportion of NSCLC (Soda et al., 2007) , first reported in 2007, presented a similar opportunity to demonstrate exceptional response in a highly selected patient population. In this case, crizotinib (PF-02341066) was under investigation as a c-met/HGF inhibitor in a Phase I study of patients with unselected solid tumors. On the basis of its recognized activity against ALK (anaplastic lymphoma kinase), the discovery of this driver in NSCLC allowed the repurposing of crizotinib and amending of the trial to include expansion cohorts enriched for the ALK fusion. This enabled rapid accrual of this relatively uncommon molecularly defined subtype, and in 2010, the initial report demonstrating a response rate of >50% in 82-ALK rearranged patients treated on this open-label Phase I study supported the accelerated approval of crizotinib (Kazandjian et al., 2014; Kwak et al., 2010) .
Next-Generation Targeted Agents
The development of ALK inhibitors also illustrates the phenomenon of rapid and sequential development of optimized agents, following demonstration of the clinical value of an anticancer target. While there are many historical examples of iterations on cytotoxic drugs (e.g., taxanes), iterations on molecular targeted therapies are being developed at an increasing pace to overcome limitations of first-generation agents. Both inhibitors of epidermal growth factor receptor (EGFR) and ALK have seen the development of new compounds able to surmount common mutational mechanisms of resistance or designed to improve penetration into the central nervous system. With a well-defined population of interest (e.g., patients resistant to the first agent), second-generation studies can be performed with great efficiency, as evidenced by ceritinib and alectinib, which entered Phase I testing in ALK rearrangement positive crizotinib failures in 2012, and was approved by the FDA in 2015. These examples are testament to the impact that clinical proof of concept can have on the field. Genomic-Based Precision Oncology Trials Increasingly, developers of molecularly targeted agents are homing in on target populations linked to putative predictive biomarkers. Knowledge of the underlying biology, as well as empiric pharmacogenomic approaches in cell line (Garnett et al., 2012) or patient-derived model platforms (Gao et al., 2015) , may inform patient selection by molecular alterations, with or without consideration of the underlying disease histology. While the principal goal of Phase I testing is to define toxicities and pharmacokinetics, incorporating biomarker selection into early phase testing may be rational for such agents and could spare the enrolment of patients who are least likely to derive any therapeutic benefit. This approach, however, adds to the complexity of patient recruitment by demanding prescreening, sometimes of large numbers of patients. Until recently, many genotypespecific trials had molecular prescreening efforts embedded within the protocols to recruit eligible patients for therapeutic interventions. These are now being usurped by more widespread clinical application of next-generation sequencing, which has become feasible and more affordable. Genomic-based trials leveraging this technology can take multiple forms but include both umbrella (randomized or non-randomized clinical trials that are histology specific, investigating different therapeutic interventions such as different drugs or drug combinations matched to molecular aberrations in a single cancer type) or basket trials (randomized or non-randomized clinical trials that are histology agnostic, investigating a therapeutic intervention such as a drug or drug combination targeting a specific molecular aberration across different cancer types). There are challenges associated with the implementation of these genomic-based trials. For instance, they often require a sufficiently broad suite of agents to enable treatment assignments, resulting in large collaborative trials such as the NCI-MATCH program, which includes drugs from multiple pharmaceutical companies (NCT02465060). The recruitment of rare genotypes into these trials requires national or international participation to ensure successful completion. Correlative Science in Early Phase Trials Underscoring the translational interactions between basic discovery and clinical development teams, correlative science studies are increasingly incorporated into early phase trials to assess pharmacodynamics and monitor response or to detect therapeutic resistance and its underlying mechanisms. While technological advances support the necessary analyses of small biopsy samples or profiling of circulating tumor markers (e.g., liquid biopsies), these add an extra layer of complexity and sometimes demand sophisticated processing, handling, and tracking of samples at participating sites. Given the added burden and costs, as well as the potential risk to participants associated with invasive procedures, it is critical that such correlative programs are scientifically justified, carefully designed, and efficiently implemented.
Future of Clinical Trials
Correlative Studies to Optimize Clinical Development While the examples described above illustrate the potential of rapid translation of preclinical discoveries into clinical successes, the underlying principles of clinical development must be anchored by thoughtful science and clinical relevance. Though timeliness and efficiency are desirable for the reasons described above, the substantial costs-measured in time, patient participation, and clinical and financial resources-demand that study design and implementation not be rushed. Robust preclinical data to understand therapeutic potential and disease biology are essential for this pursuit. However, new and emerging analytical tools enable correlative studies of clinical trials, which can increasingly shape and optimize ongoing clinical development. Beyond the pharmacokinetic and pharmacodynamic endpoints that are more traditionally considered in Phase I studies, the identification and characterization of exceptional responses and acquired resistance in these same trials present an opportunity to hone patient selection or design combination treatment strategies. Given the potential impact on subsequent scientific investigation and drug development, such correlative analyses of early phase trials should be performed and disseminated sooner. For example, acquired resistance develops in 25% of patients with melanoma achieving objective responses with PD-1 blockade, and fairly straightforward paired genomic analyses in only four pembrolizumabtreated patients permitted the recent identification of underlying alterations in interferon signaling and antigen presentation (Zaretsky et al., 2016) . Prioritization of such analyses in the early clinical trials could likely have resulted in much earlier delineation of this important biology, which has implications for ongoing development of immunotherapy strategies.
Striving for Meaningful Clinical Benefit
The ever-increasing cost of new anti-cancer therapies demands that our efforts be focused on agents that can deliver meaningful clinical benefit-defined as significant improvements in the efficacy or substantial reductions in the toxicities of existing standard of care. In addition to producing new therapies that are clinically useful and potentially cost effective, establishing a high bar for meaningful benefit requires more nimble clinical trials. Efforts by organizations such as the American Society of Clinical Oncology to establish benchmarks for clinical benefit represent an important step in the right direction (Ellis et al., 2014) . In addition to defining acceptable magnitude of benefits to justify investment in Phase III trials, more accurate means to predict success and avoid futile clinical trials are also required. Clear go-no-go criteria for agents to move from early to late-phase testing are necessary, and the bar should be set high even at this intermediate checkpoint. Assuming continued development of biomarker-driven strategies as described earlier, defining populations and predictive assays in early phase expansion cohorts offers an efficient path to identify signals of activity. However, existing limits on our knowledge of the prognostic effects of many molecular alterations makes the interpretation of time-to-event endpoints (e.g., progression-free survival) based on historical data difficult. Unless compelling objective response rates are observed to support potential paths for accelerated regulatory approval, randomized Phase II or III trial designs will often be most appropriate. While randomization generally increases the size of these intermediate or latestage trials, setting a high bar will help to contain the number of participants required. Aiming for Cure with Focus on the Adjuvant Setting While immunotherapy strategies are challenging the paradigm that metastatic solid tumors are incurable, the fact remains that the best opportunity to improve cancer survival statistics is in the adjuvant or perioperative setting, where substantially lower tumor burden could reduce the probability of drug resistance that prevents disease eradication. Development of clinical trials in this setting, particularly among patients at very high risk of lethal recurrence, needs increased focus and investment. A major challenge to advances in this area, however, remains our limited understanding of the biology of micrometastastic disease and recurrence and our inability to predict what makes a curative adjuvant treatment. Better preclinical models and more basic and translational research are urgently needed to address these gaps. In addition, because adjuvant trials are typically large, long, and expensive to conduct, improved predictors of risk and validated surrogates of benefit would be of great value to accelerate this process. Markers of minimal residual disease, such as circulating cell-free (cf)DNA, could have a place in both patient selection and dynamic monitoring of response to therapy in this setting.
Collective Wisdom in Clinical Trials
Clinical trials are constantly evolving and expanding beyond their current geographical, operational, and bioinformatic boundaries. Driven by many factors such as lower costs and faster recruitment rates, the globalization of clinical research has become an increasingly prevalent phenomenon, with a rising number of clinical trials being conducted outside of the US and other developed countries (Viergever and Li, 2015) . There are continued efforts to harmonize regulatory standards and data quality in clinical trials on a global scale, and some emerging markets have successfully achieved these goals. In addition, national and international initiatives to share data obtained from clinical trials and real-life practice are actively being pursued to enable collective learning through the power of large sample sizes (Siu et al., 2016) . These efforts will be essential to maximize the efficiency of drug development for increasingly precise clinical indications.
To summarize, landmark achievements in cancer science are providing unprecedented opportunities for improved clinical therapies (Figure 1) . By incorporating such knowledge into clinical trials and implementing non-traditional approaches to trial design, we have seen more rapid regulatory approval of several effective therapies for specific patient populations over the last decade. In the future, we expect that the development of emerging anticancer agents will necessitate increasingly innovative and agile clinical trial designs, incorporating biomarker selection and correlative science in a dynamic manner. Importantly, the success of clinical trials in delivering this progress is contingent on the engagement of key stakeholders, including academic and community physicians, basic and translational researchers, regulatory agencies, the pharmaceutical sector, patients, and advocates, to ensure that time and resources are expended to address the most important and meaningful questions to advance cancer care.
